Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma’s TriKE Bet

GT Biopharma advanced three TriKE candidates into clinical testing, with GTB-5550 dosing its first patient in a Phase 1 trial for solid tumors in May 2026, marking the company’s expansion beyond blood cancers.